Daniel Spiegelman

2019

In 2019, Daniel Spiegelman earned a total compensation of $5.2M as Former Executive Vice President, Chief Financial Officer at BioMarin Pharmaceutical, a 16% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$600,000
Option Awards$867,181
Salary$620,192
Stock Awards$3,120,022
Other$32,507
Total$5,239,902

Spiegelman received $3.1M in stock awards, accounting for 60% of the total pay in 2019.

Spiegelman also received $600K in non-equity incentive plan, $867.2K in option awards, $620.2K in salary and $32.5K in other compensation.

Rankings

In 2019, Daniel Spiegelman's compensation ranked 2,066th out of 13,971 executives tracked by ExecPay. In other words, Spiegelman earned more than 85.2% of executives.

ClassificationRankingPercentile
All
2,066
out of 13,971
85th
Division
Manufacturing
752
out of 5,692
87th
Major group
Chemicals And Allied Products
229
out of 2,189
90th
Industry group
Drugs
185
out of 1,875
90th
Industry
Pharmaceutical Preparations
134
out of 1,387
90th

Pay ratio

Daniel Spiegelman's Pay$5,239,902
Median Employee's Pay$190,917
Pay Ratio

27

to 1

In 2019, the annual total compensation of Daniel Spiegelman was $5,239,902.

The annual total compensation of the median employee at BioMarin Pharmaceutical was $190,917.

The ratio of Daniel Spiegelman's pay to the pay of median employee was therefore 27 to one.

Source: SEC filing on April 14, 2020.

Spiegelman's colleagues

We found five more compensation records of executives who worked with Daniel Spiegelman at BioMarin Pharmaceutical in 2019.

2019

Jean-Jacques Bienaim

BioMarin Pharmaceutical

Chief Executive Officer

2019

Henry Fuchs

BioMarin Pharmaceutical

President, Worldwide R&D

2019

Robert Baffi

BioMarin Pharmaceutical

President, Global Manufacturing amp; Technical Operations

2019

Jeff Ajer

BioMarin Pharmaceutical

Executive Vice President, Chief Commercial Officer

2019

Brian Mueller

BioMarin Pharmaceutical

Chief Financial Officer

News

You may also like